Toll-Like Receptor-4 Antagonist (+)-Naloxone Confers Sexually Dimorphic Protection From Inflammation-Induced Fetal Programming in Mice.

MLA

Chin, Peck Yin, et al. “Toll-Like Receptor-4 Antagonist (+)-Naloxone Confers Sexually Dimorphic Protection From Inflammation-Induced Fetal Programming in Mice.” Endocrinology, vol. 160, no. 11, Nov. 2019, pp. 2646–62. EBSCOhost, https://doi.org/10.1210/en.2019-00493.

APA

Chin, P. Y., Dorian, C., Sharkey, D. J., Hutchinson, M. R., Rice, K. C., Moldenhauer, L. M., & Robertson, S. A. (2019). Toll-Like Receptor-4 Antagonist (+)-Naloxone Confers Sexually Dimorphic Protection From Inflammation-Induced Fetal Programming in Mice. Endocrinology, 160(11), 2646–2662. https://doi.org/10.1210/en.2019-00493

Chicago

Chin, Peck Yin, Camilla Dorian, David J Sharkey, Mark R Hutchinson, Kenner C Rice, Lachlan M Moldenhauer, and Sarah A Robertson. 2019. “Toll-Like Receptor-4 Antagonist (+)-Naloxone Confers Sexually Dimorphic Protection From Inflammation-Induced Fetal Programming in Mice.” Endocrinology 160 (11): 2646–62. doi:10.1210/en.2019-00493.